8-K: Harmony Biosciences Reports Strong Q3 2024 Results, Pipeline Advances

Harmony Biosciences announced record net revenue of $186 million for Q3 2024, driven by strong sales of WAKIX and progress in its pipeline.

Summary

• Harmony Biosciences reported a record $186 million in net revenue for the third quarter of 2024, a 16% increase compared to the same period in 2023.
• The company's cumulative net revenue since the launch of WAKIX has surpassed $2 billion in less than five years.
• The average number of patients on WAKIX increased by approximately 250 sequentially to approximately 6,800 for the quarter ended September 30, 2024.
• GAAP net income for the quarter was $46.1 million, or $0.79 earnings per diluted share, compared to $38.5 million, or $0.63 earnings per diluted share, for the same period in 2023.
• Non-GAAP adjusted net income was $59.6 million, or $1.03 earnings per diluted share, for the quarter ended September 30, 2024.
• The company is on track to submit a supplemental New Drug Application (sNDA) for pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024.
• Harmony is advancing next-generation pitolisant programs, including Pitolisant-GR and Pitolisant-HD, with PDUFA goals in 2026 and 2028 respectively.
• An Investigational New Drug (IND) application for a potential best-in-class Orexin-2 agonist is on track for mid-2025.
• The company's EPX-100 program for rare epilepsies is progressing with a Phase 3 trial in Dravet Syndrome ongoing and a Phase 3 trial in Lennox-Gastaut Syndrome planned for initiation before year-end.
• Topline data from the ZYN-002 pivotal Phase 3 trial in Fragile X Syndrome is expected in mid-2025.
• Harmony Biosciences reiterates its 2024 net product revenue guidance of $700 to $720 million.
• As of September 30, 2024, Harmony had cash, cash equivalents, and investments of $504.7 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong financial results, a robust pipeline, and clear strategic direction. The company is demonstrating strong growth and is well-positioned for future success. There are some increases in operating expenses, but these are expected for a growing company.

Positives

• The company experienced a 16% increase in net product revenue compared to the same quarter last year.
• WAKIX sales continue to grow, surpassing $2 billion in cumulative revenue.
• The number of patients using WAKIX is increasing, indicating strong demand.
• The company is making progress on its pipeline with multiple programs advancing to late-stage development.
• Harmony has a strong cash position of $504.7 million.
• The company is reiterating its full-year revenue guidance of $700-$720 million.
• The company has a catalyst-rich pipeline with multiple potential product launches expected in the next five years.
• The company has a strong focus on innovation and patient impact.

Negatives

• Research and Development expenses increased by 45% compared to the same quarter in 2023.
• Total operating expenses increased by 29% compared to the same quarter in 2023.
• GAAP net income decreased by 6% for the nine months ended September 30, 2024 compared to the same period in 2023.
• The company experienced a loss on debt extinguishment of $9.8 million for the nine months ended September 30, 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There are risks associated with the commercialization of WAKIX and other product candidates.
• The company faces competition in the pharmaceutical industry.
• There are risks associated with the company's intellectual property position.
• The company's stock price may be volatile and fluctuate substantially.
• The company's ability to obtain regulatory approvals for its product candidates is not guaranteed.

Future Outlook

Harmony Biosciences anticipates one or more new product or indication launches each year over the next five years and expects its current pipeline to deliver over $3 billion in net revenue going forward. The company is focused on continuous innovation, patient impact, and long-term value creation for shareholders.

Management Comments

• Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences, stated that the company is building on its success in sleep/wake with a strategy focused on continuous innovation, patient impact, and long-term value creation for shareholders.
• He also mentioned that the company is committed to addressing unmet medical needs for people living with CNS disorders that have few or no treatment options.

Industry Context

Harmony Biosciences is operating in the competitive pharmaceutical industry, specifically within the rare neurological disease space. The company's focus on sleep/wake disorders, rare epilepsies, and neurobehavioral conditions aligns with the growing need for treatments in these areas. The company's pipeline and commercial success with WAKIX position it as a key player in the CNS therapeutics market.

Comparison to Industry Standards

• Harmony's revenue growth of 16% year-over-year is strong compared to many established pharmaceutical companies, though direct comparisons are difficult due to the company's focus on rare diseases.
• The company's pipeline, with multiple Phase 3 programs, is robust compared to many smaller biotech companies.
• The company's focus on next-generation formulations of pitolisant and novel mechanisms of action like the Orexin-2 agonist demonstrates a commitment to innovation.
• The company's cash position of $504.7 million is strong, providing financial flexibility for continued development and commercialization efforts.
• The company's success with WAKIX, achieving over $2 billion in cumulative revenue in less than five years, is a significant achievement compared to many other rare disease drug launches.

Stakeholder Impact

• Shareholders are likely to be positively impacted by the strong financial results and pipeline progress.
• Patients with narcolepsy, idiopathic hypersomnia, rare epilepsies, and Fragile X Syndrome may benefit from the company's pipeline of potential new treatments.
• Employees may benefit from the company's growth and success.
• The company's suppliers and partners may benefit from the company's continued operations and expansion.

Next Steps

• Submit sNDA for pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024.
• Initiate pivotal bioequivalence study and dosing optimization study for Pitolisant-GR in Q1 2025.
• Submit IND for Orexin-2 agonist in mid-2025.
• Initiate Phase 3 trial for EPX-100 in Lennox-Gastaut Syndrome in Q4 2024.
• Continue Phase 3 trial for EPX-100 in Dravet Syndrome.
• Continue Phase 3 trial for ZYN-002 in Fragile X Syndrome.
• Initiate pivotal Phase 3 trial in 22q11.2 deletion syndrome in 2025.

Key Dates

Keywords

Harmony Biosciences, WAKIX, pitolisant, narcolepsy, idiopathic hypersomnia, rare epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Fragile X Syndrome, ZYN-002, EPX-100, EPX-200, Orexin-2 agonist, CNS disorders, pharmaceuticals, biotechnology